Worldwide COPD and Asthma Devices Market to 2027 - Opportunity Analysis and Industry Forecast - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "COPD and Asthma Devices Market by Product Type, Indication and Distribution Channel: Global Opportunity Analysis and Industry Forecast 2020-2027" report has been added to ResearchAndMarkets.com's offering.

The global COPD and asthma devices market is expected to reach $51,628.58 million by 2027, registering a CAGR of 4.30% during 2020-2027.

Chronic obstructive pulmonary disease (COPD) and asthma devices, also known as pulmonary drug delivery devices, are used as a permanent treatment or rescue therapy for respiratory diseases and other related ailments. It is the most advanced mode of drug administration in which the drug is directly delivered to the lungs to provide a systemic effect. COPD and asthma have significant shares in the global respiratory diseases market. According to the Global Health Organization (WHO), in 2016, around 251 million cases of COPD were estimated globally. Thus, a variety of drug-delivery protocols, such as oral and parenteral delivery, are developed for the treatment of COPD and asthma. However, the pulmonary drug delivery system is the most effective treatment option as compared to the other conventional methods.

The major factors that drive market growth are an increase in concerns of respiratory diseases, such as asthma and emphysema, and a rise in incidences of respiratory diseases caused due to cigarette consumption. Furthermore, an increase in healthcare expenditure, growth in use of automation in the healthcare industry, and rapid adoption of advanced medical solutions also boost market growth. Currently, most of healthcare practitioners and pulmonary diseases specialists prefer a combination of a drug and a device, for instance, inhaler and nebulizer, owing to its fast and effective outcome. However, the factors such as high cost associated with nebulizers, side effects occurring due to excessive dosage, and lack of awareness regarding drug inhalation are expected to restrain the growth of the market. On the contrary, introduction of smart inhaler drives the opportunity for the growth of COPD and asthma devices market in near future.

The global COPD and asthma devices market is segmented on the basis of product type, indication, distributional channel, and region. Based on the device type, the market is segmented into inhalers and nebulizers. Furthermore, the inhalers segment includes dry powder inhalers (DPIs), metered dose inhalers (MDIs), and soft mist inhalers (SMIs). However, the nebulizers segment includes compressor nebulizers, ultrasonic nebulizers, and mesh nebulizers. Based on indication, the market is divided into asthma and COPD. Based on the distribution channel, it is segregated into retail pharmacies, online pharmacies, and hospitals. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. These regions are further analyzed on the basis of the respective countries.

Key Benefits

• This report entails a detailed quantitative analysis along with the current global antihypertensive market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessment.
• The market size and estimations are based on a comprehensive analysis of key developments in the industry.
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.

Market Dynamics

Drivers

• Daily Exposure to Environmental Pollution
• Increase in Population Susceptible to Indoor Air Pollutants
• Portability of the Drug Delivery Devices
• Increasing Population of Active Smokers
• Rising Government Initiatives

Restraints

• Increase in Price Competition and Deterioration of Material Quality
• Overall High Cost of Asthma Treatment is a Challenge for the Patients
• Incompetent Reimbursement Support

Opportunities

• Patent Expiration for Blockbuster Drugs
• Smart Inhaler: Future Growth Driver

Companies Mentioned

• Aerogen Inc
• AstraZeneca PLC
• Baxter International Inc
• Boehringer Ingelheim International GmbH
• 3M COMPANY
• GF Health Products
• GlaxoSmithKline Plc
• Koninklijke Philips NV
• Novartis AG
• PARI medical Holding GMBH
• Smith's Group Plc

For more information about this report visit https://www.researchandmarkets.com/r/qdhi2d